A fire broke out this morning around 4:20 am outside of a small production workshop at our site in Chasse-sur-Rhône.
Leveraging on its recent investments Senrise-IV and Senefill, Novasep launches a unique
2-year turnkey plant offer to accelerate commercial production of viral vectors.
Senefill will be commissioned on October 1, 2019 and will offer Fill & Finish clinical and commercial services for biological products, from formulation to packaging.
This agreement supports the growing demand for lentivector-based gene therapies, immunotherapies and vaccines
• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.
Novasep Holding S.A.S (“Novasep”), a leading supplier of services and technologies for the life sciences industry, announces the launch of a consent solicitation (the “Consent Solicitation”) in order to, inter alia:
This represents a step forward for the plant-based protein purification industry, with the first compact bed chromatography system for the purification of vegetable proteins.
With this new Viral Vector bioproduction facility, Novasep confirms its leadership position and effectively addresses the growing gene therapy market demand
Novasep’s robust quality assurance system, fully compliant with the highest world standards, showcased during successful FDA inspection of the Chasse-sur-Rhône (France) facility.